Imaging and Biomarker Core

成像和生物标志物核心

• 批准号: 10661547
• 负责人: Thomas J. Grabowski
• 金额: $ 23.17万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-01 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10661547
• 关键词: Abbreviations; Alaska Native; Alzheimer' s Disease; Alzheimer' s disease related dementia; American Indians; Anatomy; Architecture; Archives; Automobile Driving; Autopsy; Biological Markers; Blood; Brain; Brain region; Cerebral cortex; Characteristics; Classification; Clinic; Clinical; Cognition; Cognitive; Data; Data Analyses; Data Science; Data Set; Dementia; Dimensions; Enrollment; Ensure; Foundations; Funding; Genetic; Goals; Heterogeneity; Image; Image Analysis; Impaired cognition; Informatics; Letters; Link; Liquid substance; MRI Scans; Machine Learning; Magnetic Resonance Imaging; Maps; Measures; Memory; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; Nerve Degeneration; Participant; Pathologic; Pattern; Phenotype; Positron-Emission Tomography; Process; Quality Control; Research; Research Personnel; Resources; Sampling; Source; Specificity; Structure; Tissue Sample; Universities; Washington; Wellness Center; biological heterogeneity; cell repository; central database; cohort; data management; education research; human subject; imaging study; in vivo; medical schools; molecular imaging; multidisciplinary; neuroimaging; neuropathology; novel; outreach; phenotypic data; recruit; repository; resilience; statistics

Abstract The Imaging and Biomarker (IB) Core will characterize participants in the Clinical Core through neuroimaging and fluid biomarker analysis, in conformity with prevailing standards. A further focus is to rigorously describe topographic phenotypes of the participants and to link this information to cognitive, fluid biomarker, genetic, and neuropathologic data generated by the Center. The Core will also provide an information architecture and consulting expertise to represent the imaging data to ADRC-affiliated studies and investigators. Many UW ADRC-affiliated studies require human subjects who are well-characterized with imaging and fluid biomarkers. MRI imaging will be obtained on all normal cognition, MCI, and mild AD participants in the Clinical and Native Research and Resource (NRRC) Cores. We will characterize our Clinical Core cohort with A|T|N classification, primarily with CSF biomarkers (A, T) and MRI (N) imaging. The IB Core will coordinate PET scans in ADRC affiliate projects or co-enroll affiliate subjects in the Clinical Core to ensure Clinical Core subjects have PET scanning performed. We provide expertise in planning and analyzing PET molecular imaging studies. Affiliated studies are investigating specific candidate mechanisms of AD, as well as whether, and why, different pathological mechanisms inherent in AD have differing patterns of impact over the cerebral cortex. For such studies, the brain space is a point of integration of the other biomarkers of AD. We have organized the IB Core and its interactions with the Clinical and Neuropathology Cores such that topographical heterogeneity, determined from imaging data, is incorporated as a phenotypic characteristic, along with cognitive domain, fluid biomarker, and genetic data. We will measure cortical degeneration, as well as cortical sparing, across a set of brain regions that represent the range and variability of involvement in AD. Another important aspect of cognitive variability is the relationship of the degree of cognitive impairment that results from a given degree of neurodegeneration (cognitive resilience). Thus we will also extract measures of cognitive resilience from cognitive and anatomic data, as another phenotypic dimension. We will provide consulting expertise in informatics/machine learning, image analysis and statistics for the description and analysis of these data. We have also structured the Core to support the same multidisciplinary phenotyping in decedents from the Clinical cohort who come to autopsy. We will perform ex vivo MRI in all, and process structural measures as in the in vivo studies. We will sample tissue from the same regions that we target with imaging in living participants. We will calculate analogous resilience measures. Ex vivo MRI will also enable targeted sampling of MRI-apparent abnormalities at autopsy and mapping neuropathologic data into standard anatomical space.

抽象的 成像和生物标志物（IB）核心将通过神经成像来表征临床核心的参与者 和流体生物标志物分析，符合普遍标准。另一个重点是严格描述 参与者的地形表型，并将这些信息与认知，流体生物标志物，遗传， 和中心生成的神经病理数据。核心还将提供信息体系结构，并 咨询专业知识，以代表与ADRC相关研究和研究人员的成像数据。 许多UW ADRC附属研究都需要具有成像和成像良好特征的人类受试者 流体生物标志物。将在所有正常认知，MCI和轻度AD参与者中获得MRI成像 临床和本地研究与资源（NRRC）核心。我们将与我们的临床核心队列进行表征 A | T | N分类主要是CSF生物标志物（A，T）和MRI（N）成像。 IB核心将协调 PET扫描ADRC会员项目或临床核心的共同入学会员，以确保临床核心 受试者进行了PET扫描。我们提供计划和分析宠物分子的专业知识 成像研究。 附属研究正​​在研究AD的特定候选机制，以及是否以及为什么，为什么 AD固有的不同病理机制对大脑皮层具有不同的影响模式。为了 这样的研究，大脑空间是AD其他生物标志物的整合点。我们已经组织了IB 核心及其与临床和神经病理学核心的相互作用，使得地形异质性， 由成像数据确定，并将其作为表型特征以及认知域，流体合并 生物标志物和遗传数据。我们将在一组中测量皮质变性和皮质差异 代表参与AD的范围和可变性的大脑区域的。另一个重要方面 认知差异是认知障碍程度的关系，该程度是由给定程度的 神经变性（认知弹性）。因此，我们还将从 认知和解剖学数据，作为另一个表型维度。我们将提供咨询专业知识 信息学/机器学习，图像分析和统计数据，以描述和分析这些数据。 我们还构建了核心，以支持来自 开始尸检的临床队列。我们将全部执行体内MRI，并处理结构测量 就像在体内研究中一样。我们将从同一区域中采样组织的组织 参与者。我们将计算类似的弹性措施。离体MRI也将启用目标采样 尸检和将神经病理学数据映射到标准解剖空间中的MRI异常。